Scaling Viral Vectors

Scalability remains a challenge for viral vectors. Short shelf life of viral vectors to be an issue, and so too, do single use technologies as businesses scale their viral vector manufacturing. Here, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO cover the high operational costs associated with viral vectors.